Literature DB >> 25208656

Cardiomyocyte apoptosis vs autophagy with prolonged doxorubicin treatment: comparison with osteosarcoma cells.

Oktay Tacar1, Sivanjah Indumathy, Mei Lin Tan, Swati Baindur-Hudson, Anna M Friedhuber, Crispin R Dass.   

Abstract

OBJECTIVE: Doxorubicin (Dox) is a frontline chemotherapeutic against osteosarcoma (OS) that is plagued by side effects, particularly in the heart. The specific objective of this article is to investigate whether low-dose Dox treatment had pro-autophagic effects in cardiomyocytes as well as osteosarcoma cells.
METHODS: This study characterises apoptotic (Bax) and autophagic (Beclin-1) biomarker levels in human OS and cardiomyocyte cell lines as well as in various tissues when mice are exposed to low (1 mg/kg, thrice weekly) and high (3 mg/kg thrice weekly) dose Dox for a month. KEY
FINDINGS: There was a decrease in Bax and increase in Beclin-1 in cardiac tissue in the high-dose group. Dox decreased Beclin-1 in the skin and liver, with no clear indication in the stomach, small intestine and testis. At low Dox doses of 10 and 100 nm in cardiomyocytes and OS cells, there is a pro-apoptotic effect, with a quicker response in the 100-nm condition, and a slower but steady increase of a pro-apoptotic response at the lower 10-nm dose. However, electron microscopy images revealed changes to human OS cells that resembled autophagy. Human prostate, breast and colorectal cells treated with 10-nm Dox showed ∼ 40% reduction in cell viability after 24 h.
CONCLUSION: In culture, cells of both cardiomyocytes and OS revealed a predominant pro-apoptotic response at the expense of autophagy, although both seemed to be occurring in vivo.
© 2014 Royal Pharmaceutical Society.

Entities:  

Keywords:  Bax; Beclin-1; apoptosis; autophagy; cardiotoxicity

Mesh:

Substances:

Year:  2014        PMID: 25208656     DOI: 10.1111/jphp.12324

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  6 in total

1.  Protective effect of flavonoids from Rosa roxburghii Tratt on myocardial cells via autophagy.

Authors:  Huifang Yuan; Yiru Wang; Hui Chen; Xinhua Cai
Journal:  3 Biotech       Date:  2020-01-22       Impact factor: 2.406

Review 2.  Doxorubicin-induced chronic dilated cardiomyopathy-the apoptosis hypothesis revisited.

Authors:  Cynthia Kankeu; Kylie Clarke; Egle Passante; Heinrich J Huber
Journal:  J Mol Med (Berl)       Date:  2016-12-08       Impact factor: 4.599

3.  Paeoniflorin inhibits doxorubicin-induced cardiomyocyte apoptosis by downregulating microRNA-1 expression.

Authors:  Jian-Zhe Li; Xiu-Neng Tang; Ting-Ting Li; Li-Juan Liu; Shu-Yi Yu; Guang-Yu Zhou; Qing-Rui Shao; Hui-Ping Sun; Cheng Wu; Yang Yang
Journal:  Exp Ther Med       Date:  2016-03-24       Impact factor: 2.447

4.  New small molecules targeting apoptosis and cell viability in osteosarcoma.

Authors:  Doris Maugg; Ina Rothenaigner; Kenji Schorpp; Harish Kumar Potukuchi; Eberhard Korsching; Daniel Baumhoer; Kamyar Hadian; Jan Smida; Michaela Nathrath
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

5.  Reversible Treatment of Pressure Overload-Induced Left Ventricular Hypertrophy through Drd5 Nucleic Acid Delivery Mediated by Functional Polyaminoglycoside.

Authors:  Xiaoliang Jiang; Meiyu Shao; Xue Liu; Xing Liu; Xu Zhang; Yuming Wang; Kunlun Yin; Shuiyun Wang; Yang Hu; Pedro A Jose; Zhou Zhou; Fu-Jian Xu; Zhiwei Yang
Journal:  Adv Sci (Weinh)       Date:  2021-01-06       Impact factor: 16.806

6.  Nauclea orientalis (L.) Bark Extract Protects Rat Cardiomyocytes from Doxorubicin-Induced Oxidative Stress, Inflammation, Apoptosis, and DNA Fragmentation.

Authors:  Jayasinghe A N Sandamali; Ruwani P Hewawasam; Kamani A P W Jayatilaka; Lakmini K B Mudduwa
Journal:  Oxid Med Cell Longev       Date:  2022-02-14       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.